Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
392 participants
Oct 29, 2024
INTERVENTIONAL
Conditions
Summary
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive assigned dose of BBO-10203 orally once daily
Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
Patients will receive FOLFOX as infusion every 14 days
Patients will receive bevacizumab as infusion every 28 days
Locations(36)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06625775